MYLK and cancer: Disruption of dormant cancer cell survival and recurrence can be achieved by blocking integrin β1 signaling with antibodies in the fibrotic marrow [223,358], blocking myosin light chain kinase (MLCK) activation by integrin β1 to prevent the formation of F-actin and proliferative growth [104], blocking fibronectin attachment [98] or downregulating integrin β1 expression with flavopiridol to decrease attachment and survival of dormant ER+ BC clones [119].